-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] News on December 30th, the pharmaceutical sector changed, and many stocks were active.
As of 10:50, Longjin Pharmaceutical had 7 consecutive boards, and Essence Pharmaceuticals had recorded 6 consecutive boards in 7 trading days.
In addition, Anxu Biology, Longshen Rongfa, Zhongxin Pharmaceutical, Yahuilong, Lexin Medical, and Xinhua Medical were among the top gainers
.
Longjin Pharmaceutical closed 7 daily limit in a row.
Among them, Longjin Pharmaceutical opened the daily limit on December 30, and has closed 7 daily limit in a row
.
As of 10:50, the stock rose 9.
98%, with a quotation of 14.
66 yuan, a turnover of 372 million, and a turnover rate of 6.
48%
.
Longjin Pharmaceutical is a traditional Chinese medicine stock.
According to the analysis, there are two reasons for the change of the stock: First, the company is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs
.
The company's main product is breviscapine for Longjin injection, which is a high-purity traditional Chinese medicine freeze-dried powder injection.
The product has the functions of promoting blood circulation, removing blood stasis, clearing collaterals and relieving pain.
Coronary heart disease, angina pectoris; Second, the company increased its capital in Yunnan Muya Agricultural Technology Co.
, Ltd.
(Muya Agriculture) by RMB 15 million, and obtained 51% of its equity
.
The main business of Muya Agriculture is the large-scale cultivation of industrial hemp
.
On December 29, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, stating that the company’s closing price increase deviation value accumulated to 29.
89% within three consecutive trading days (December 27, December 28, and December 29, 2021).
, according to the "Shenzhen Stock Exchange Trading Rules", it belongs to the abnormal fluctuation of stock trading
.
After verification, the controlling shareholder and actual controller do not have any major events that should be disclosed but have not been disclosed, nor do they have major events in the planning stage; the company's recent operations are normal, and the internal and external operating environment has not undergone major changes.
Currently, there are no major events.
Material matters that should be disclosed but not disclosed
.
Essence Pharma hit the daily limit again Essence Pharma hit the daily limit again on December 30, recording 6 daily limits in 7 trading days
.
The stock has risen by the limit 10 times in the past year
.
As of 10:50, the stock rose 9.
98%, with a quotation of 10.
25 yuan, a turnover of 42.
43 million, and a turnover rate of 0.
50%
.
Like Longjin Pharmaceuticals, Essence Pharmaceuticals is also a Chinese medicine stock
.
According to the analysis, there are three reasons for the change of Essence Pharmaceuticals: First, the company is a company mainly engaged in the research and development and production of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals.
Second, Jiangsu Suxin Pharmaceutical Co.
, Ltd.
, a subsidiary of the company’s subsidiary Jiangsu Kingsley Pharmaceutical Co.
, Ltd.
, established Yixing Suxin Pension Industry Development Co.
, Ltd.
in May 2020; third, the company’s holding subsidiary Senxuan Pharmaceutical plans to declare to be listed on the selection layer, and the company holds 84.
14% of the shares
.
In December, the performance of the traditional Chinese medicine sector was significantly stronger than the market.
Recently, the traditional Chinese medicine sector has moved up.
According to the news, since December, the prices of many Chinese herbal medicines have risen, and even the supply of proprietary Chinese medicines by pharmaceutical companies has been in short supply, such as common Coptis chinensis, honeysuckle, skullcap, etc.
, as well as new varieties of medicinal and food homologous such as tangerine peel, dendrobium and so on
.
In this regard, some research institutions pointed out that the development of traditional Chinese medicine consumer goods has ushered in great opportunities: Since 2021, the price of upstream Chinese medicinal materials has continued to rise, and there is a certain price increase expected for upstream raw materials + downstream products in the future; the industry channel inventory clearance is coming to an end, and the superimposed price increase is expected to bring The downstream inventory turnover speed has accelerated; the mixed ownership reform of relevant state-owned enterprises and the positive changes at the shareholder level, the future performance is expected to improve significantly
.
As of 10:50, Longjin Pharmaceutical had 7 consecutive boards, and Essence Pharmaceuticals had recorded 6 consecutive boards in 7 trading days.
In addition, Anxu Biology, Longshen Rongfa, Zhongxin Pharmaceutical, Yahuilong, Lexin Medical, and Xinhua Medical were among the top gainers
.
Longjin Pharmaceutical closed 7 daily limit in a row.
Among them, Longjin Pharmaceutical opened the daily limit on December 30, and has closed 7 daily limit in a row
.
As of 10:50, the stock rose 9.
98%, with a quotation of 14.
66 yuan, a turnover of 372 million, and a turnover rate of 6.
48%
.
Longjin Pharmaceutical is a traditional Chinese medicine stock.
According to the analysis, there are two reasons for the change of the stock: First, the company is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs
.
The company's main product is breviscapine for Longjin injection, which is a high-purity traditional Chinese medicine freeze-dried powder injection.
The product has the functions of promoting blood circulation, removing blood stasis, clearing collaterals and relieving pain.
Coronary heart disease, angina pectoris; Second, the company increased its capital in Yunnan Muya Agricultural Technology Co.
, Ltd.
(Muya Agriculture) by RMB 15 million, and obtained 51% of its equity
.
The main business of Muya Agriculture is the large-scale cultivation of industrial hemp
.
On December 29, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, stating that the company’s closing price increase deviation value accumulated to 29.
89% within three consecutive trading days (December 27, December 28, and December 29, 2021).
, according to the "Shenzhen Stock Exchange Trading Rules", it belongs to the abnormal fluctuation of stock trading
.
After verification, the controlling shareholder and actual controller do not have any major events that should be disclosed but have not been disclosed, nor do they have major events in the planning stage; the company's recent operations are normal, and the internal and external operating environment has not undergone major changes.
Currently, there are no major events.
Material matters that should be disclosed but not disclosed
.
Essence Pharma hit the daily limit again Essence Pharma hit the daily limit again on December 30, recording 6 daily limits in 7 trading days
.
The stock has risen by the limit 10 times in the past year
.
As of 10:50, the stock rose 9.
98%, with a quotation of 10.
25 yuan, a turnover of 42.
43 million, and a turnover rate of 0.
50%
.
Like Longjin Pharmaceuticals, Essence Pharmaceuticals is also a Chinese medicine stock
.
According to the analysis, there are three reasons for the change of Essence Pharmaceuticals: First, the company is a company mainly engaged in the research and development and production of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals.
Second, Jiangsu Suxin Pharmaceutical Co.
, Ltd.
, a subsidiary of the company’s subsidiary Jiangsu Kingsley Pharmaceutical Co.
, Ltd.
, established Yixing Suxin Pension Industry Development Co.
, Ltd.
in May 2020; third, the company’s holding subsidiary Senxuan Pharmaceutical plans to declare to be listed on the selection layer, and the company holds 84.
14% of the shares
.
In December, the performance of the traditional Chinese medicine sector was significantly stronger than the market.
Recently, the traditional Chinese medicine sector has moved up.
According to the news, since December, the prices of many Chinese herbal medicines have risen, and even the supply of proprietary Chinese medicines by pharmaceutical companies has been in short supply, such as common Coptis chinensis, honeysuckle, skullcap, etc.
, as well as new varieties of medicinal and food homologous such as tangerine peel, dendrobium and so on
.
In this regard, some research institutions pointed out that the development of traditional Chinese medicine consumer goods has ushered in great opportunities: Since 2021, the price of upstream Chinese medicinal materials has continued to rise, and there is a certain price increase expected for upstream raw materials + downstream products in the future; the industry channel inventory clearance is coming to an end, and the superimposed price increase is expected to bring The downstream inventory turnover speed has accelerated; the mixed ownership reform of relevant state-owned enterprises and the positive changes at the shareholder level, the future performance is expected to improve significantly
.
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
